Add BrightSurf on Google Email

Combination therapy with stem cell-derived immune cells boost anti-cancer response

A recent study reveals that combining iNKT cell therapy with antigen-presenting cells activated by a lipid compound triggers effective antitumor immunity. The therapy generates memory-phenotype T cells that can recognize and respond to specific threats, offering a promising personalized approach to cancer treatment.

SourceChiba University·JournalStem Cell Research & Therapy·TypeExperimental study·DateMay 7, 2026

Reinvigorating exhausted T cells in cancer and chronic viral infections cells. However, in chronic viral infection and cancer, the killer cells often lapse into “exhausted” CD8+ T cells that no longer can stem disease

Researchers at University of Alabama at Birmingham identify Gfi1 as a crucial regulator of exhausted CD8+ T cell subsets. Fine-tuning Gfi1 activity may prevent or reverse T cell exhaustion, bolstering immune checkpoint blockade therapy. The study suggests potential for improving cancer treatment and controlling chronic infections.

SourceUniversity of Alabama at Birmingham·JournalNature Communications·TypeExperimental study·DateAug 4, 2025

Scientists at The Wistar Institute’s HIV Cure and Viral Diseases Center develop new natural killer cell strategy to target HIV

Researchers at The Wistar Institute's HIV Cure and Viral Diseases Center have identified a new approach using natural killer cells to target and kill HIV-positive cells. CD64 expression enhances binding activity for holding onto antigen-specific antibodies, allowing for specific targeting and killing of infected cells.

SourceThe Wistar Institute·JournalJournal of Immunology·TypeExperimental study·DateFeb 17, 2025

Natural killer cell cellular-based therapeutic options to manage acute myeloid leukemia: prospects and challenges

Natural Killer (NK) cell-based therapies have shown promise in preclinical and clinical studies for treating Acute Myeloid Leukemia (AML), offering a potential cure with minimal prior antigen sensitization. However, the dysfunction of NK cells in AML patients poses a significant challenge that must be overcome to unlock their full ther...

SourceXia & He Publishing Inc.·JournalOncology Advances·DateSep 30, 2024

Newly discovered mechanism of T-cell control can interfere with cancer immunotherapies

Researchers at DKFZ and UMM found that NK cells can impair the effect of cancer therapies using immune checkpoint inhibitors by controlling activated T cells. They identified B7H6 as a recognition molecule for NK cell attacks, which could limit excessive activation and expansion of T cells.

New cell therapy shows promise with ARDS patients

A new type of cell therapy has shown promising results in improving survival rates and reducing pneumonia among critically ill ARDS patients recovering from severe Covid-19. The invariant natural killer T (iNKT) cell therapy, known as agenT-797, triggered an anti-inflammatory response and activated anti-viral immunity.

SourceAnglia Ruskin University·JournalNature Communications·DateFeb 6, 2024

CAR-NKT cell therapy shows promising results against neuroblastoma in phase 1 clinical trial

Researchers at Baylor College of Medicine report well-tolerated CAR-NKT cell therapy with strong antitumor activity in patients with stage 4 relapsed neuroblastoma. The treatment, which targets a molecule found on the surface of neuroblastoma cells, showed encouraging results in three patients with complete and partial responses.

SourceBaylor College of Medicine·JournalNature Medicine·DateMay 15, 2023

Immunotherapy reduces lung and liver fibrosis in mice

Researchers at the University of Zurich have developed a new immunotherapy strategy to eliminate fibroblasts in targeted manner, reducing lung and liver fibrosis in mice. The treatment triggers an immune response via cytotoxic T-cells, eliminating activated connective tissue cells while leaving resting cells undamaged.

SourceUniversity of Zurich·JournalCell Stem Cell·TypeExperimental study·DateSep 15, 2022

UCLA scientists make strides toward an ‘off-the-shelf’ immune cell therapy for cancer

Researchers produce large quantities of powerful cancer-fighting iNKT cells using stem cell engineering and organoid technology, offering a potential solution for mass-producing an off-the-shelf immune cell therapy. The therapy, which uses hematopoietic stem cell-engineered iNKT cells, has been shown to be effective in killing multiple...

SourceUniversity of California - Los Angeles Health Sciences·JournalCell Reports Medicine·TypeExperimental study·DateNov 16, 2021

A new pathway to 'reprogram' killer cells

Researchers at the University of Bern have found that killer cells without TRAIL become 'tamer', producing more messenger molecules to activate other immune cells, and resulting in better protection against viruses. This alternative signaling pathway could be used to reprogram killer cells for cancer immunotherapy.

SourceUniversity of Bern·JournalEMBO Reports·DateNov 19, 2019

CAR-T immunotherapies may have a new player

Researchers at University of California San Diego School of Medicine and University of Minnesota have developed a new CAR-T immunotherapy using natural killer cells engineered from human induced pluripotent stem cells. These cells demonstrated heightened activity against ovarian cancer with less toxicity, offering potential advantages ...

SourceUniversity of California - San Diego·JournalCell Stem Cell·DateJun 28, 2018

Protecting the body from itself

Researchers have established a crucial relationship between Natural Killer T (NKT) cells and B cells in the body's natural defense mechanisms. The study found that altered lipid compositions on autoimmune B cells lead to over-activation of NKT cells, causing their depletion. Removing a specific lipid-presenting molecule from B cells re...

SourceBiomedical Sciences Institutes (BMSI)·JournalCell Reports·DateSep 25, 2014

Invisibility cloak for immune cells

Scientists at ETH Zurich have identified a mechanism that protects immune cells from natural killer cells. Type I interferon receptors play a crucial role in this process, and its absence can lead to the elimination of healthy immune cells. This discovery may have implications for understanding autoimmune diseases.

SourceETH Zurich·JournalImmunity·DateJun 25, 2014